OHRENCIA® (abatacept) 125mg
Product Overview
| Generic Name | OHRENCIA® (abatacept) 125mg |
| Brand Name(s) | OHRENCIA®, Orencia® |
| Category | Immuno Therapies |
| Form | Solution for subcutaneous injection in four (4) prefilled syringes |
| Strength | 125 mg/mL |
| Therapeutic Class | Selective T-cell co-stimulation modulator; inhibits T-cell activation |
| ATC Code | L04AA24 |
Manufacturing & Regulatory
| Manufacturer | BMS |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5820.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 5 units |
| Shelf Life | 24 Months |
| Storage | Refrigerate 2–8°C; do not freeze |
| Incoterms | ExW, HS/HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| CTD Summary (PDF) | CTD available to regulators; summary available to qualified partners |
Special Notes
OHRENCIA (Abatacept) is a biologic selective co-stimulation modulator used for moderate-to-severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis, depending jurisdictional label.